Primary Prevention of <i>Clostridioides difficile</i> Infection With Oral Vancomycin in Pediatric Hematopoietic Stem Cell Transplant Patients
Empiric OVP during pediatric HSCT hospitalization was associated with a markedly low CDI incidence. Despite theoretical risks of microbiome disruption, no adverse effects were identified in this cohort, including long-term follow-up beyond 5 years. These findings support the safety and potential efficacy of OVP as primary CDI prophylaxis in pediatric HSCT patients.
Authors
- Zachary LeBlanc (ORCID: https://orcid.org/0000-0002-0980-3374)
- Heather Valdin (ORCID: https://orcid.org/0009-0005-8980-7808)
- Lolie C. Yu
- Mackenzie Creamer (ORCID: https://orcid.org/0009-0002-7737-269X)
- Gregory Cook
- Blake Gray
Institutions
- Children's Hospital of New Orleans (US)
- Louisiana State University Health Sciences Center New Orleans (US)
Publication Details
- Journal
- Pediatric Transplantation
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/petr.70246
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00